Physicians and researchers at the Netherlands Cancer Institute have unveiled a groundbreaking artificial intelligence (AI) model that fundamentally reshapes how treatment responses in pleural mesothelioma—a notoriously challenging cancer—are evaluated. This model, called ARTIMES, excels beyond traditional clinical methods, surpassing expert human judgment in accuracy and efficiency. By precisely measuring the entire tumor volume instead of relying on conventional diameter-based assessments, ARTIMES promises to revolutionize patient care and accelerate clinical research in this difficult-to-treat disease.

Pleural mesothelioma poses unique diagnostic challenges because it develops as a thin, irregular layer along the lining of the lungs rather than forming discrete masses. This morphology renders existing international standards like the RECIST (Response Evaluation Criteria in Solid Tumors) inadequate. RECIST depends primarily on simple diameter measures, which poorly represent the tumor’s true progression or regression in mesothelioma’s diffuse growth pattern. Clinicians have expressed frustration and uncertainty in evaluating treatment efficacy using these parameters, highlighting a pressing need for a more refined and reliable approach.

To address these limitations, an interdisciplinary team of AI scientists, radiologists, and pulmonologists collaborated at the Netherlands Cancer Institute. Leveraging an extensive dataset comprising over 11,000 computed tomography (CT) scans from more than 2,000 patients across 121 hospitals worldwide, they developed ARTIMES, an AI-driven volumetric response evaluation tool. Unlike humans, who face near-impossible challenges in manually delineating tumor boundaries at the pixel level on complex images, ARTIMES can effortlessly segment entire tumors and calculate their true volume with exceptional precision.

Pulmonologist Sjaak Burgers emphasizes that ARTIMES advances clinical practice by eliminating tedious and error-prone manual tumor assessments. While verifying the AI’s output remains essential, the review process is far less labor-intensive. This reduces interobserver variability and enables clinicians to obtain more consistent and objective insights into tumor dynamics. The ability to evaluate the full tumor burden rather than a single diameter mark dramatically increases sensitivity for detecting true positive or negative treatment responses.

The scientific community is witnessing a milestone with ARTIMES being the first AI model worldwide to demonstrably outperform clinicians in assessing treatment outcomes for pleural mesothelioma. Kevin Groot Lipman, lead author and technical physician, highlights that their study, published in The Lancet Oncology, cements AI’s potential to become an integral clinical decision support tool. Importantly, ARTIMES enhances rather than replaces physician judgment, interfacing smoothly into existing workflows while enabling rapid, data-driven decision-making.

Beyond measuring tumor volume, the researchers have undertaken the critical task of integrating ARTIMES measurements into actionable clinical guidelines. Since knowing the tumor size alone does not dictate specific treatment changes, these criteria empower pulmonologists to determine when to modify or cease therapies. This synergy ensures that patients receive individualized care tailored to their tumor behavior patterns, reducing exposure to ineffective treatments and unnecessary side effects while optimizing healthcare resources.

One of ARTIMES’s most transformative capabilities is its ability to detect non-response to therapy earlier than ever before. This timely recognition allows physicians to pivot treatment plans sooner, offering patients alternative therapeutic avenues or sparing them from futile and potentially harmful continuation of ineffective regimens. The combination of predictive accuracy and clinical oversight represents a major leap forward in precision oncology for pleural mesothelioma patients.

Currently, EU regulations restrict ARTIMES’s use exclusively to the Netherlands Cancer Institute under an in-house exemption, given that the model was developed internally. Nonetheless, the research team is actively pursuing regulatory approval to deploy ARTIMES globally in other hospitals. There is hopeful anticipation surrounding proposed EU frameworks aimed at streamlining the certification process for AI-enabled medical devices, which could accelerate widespread adoption and patient benefit.

The advent of ARTIMES is poised to deliver a shockwave across oncology fields by demonstrating the tangible superiority of AI over human evaluators in complex tumor assessments. To foster transparency and collaborative innovation, the Netherlands Cancer Institute has made the mesothelioma AI model publicly accessible online, enabling researchers worldwide to explore and extend its applications. This open science approach is expected to catalyze new studies and adaptations for other tumor types with challenging morphologies.

Already, the NKI team is extending their AI methodologies to address lung cancer and brain metastasis tumor evaluations. The success of ARTIMES signals the dawn of a new epoch in oncological imaging, where volumetric and morphological complexities that previously hindered precise quantification become tractable. Such breakthroughs unlock significant potential to enhance clinical trial design by furnishing robust, reproducible endpoints that more faithfully capture therapeutic impact.

Clinical trials for novel treatments stand to gain markedly from ARTIMES’s introduction. Using data from eight distinct trials, the research team validated that AI-guided volumetric criteria yield significantly improved accuracy relative to traditional RECIST assessments. This refined precision enables better evaluation of an investigational drug’s efficacy, ultimately accelerating regulatory approval timelines and facilitating faster patient access to promising therapies.

In summary, ARTIMES exemplifies how synergistic integration of AI and clinical expertise can surmount longstanding challenges in tumor measurement. By transitioning from simplistic unidimensional diameter metrics to comprehensive volumetric analysis, this technology brings unprecedented clarity and confidence to oncological decision-making. As this AI model becomes more widely disseminated and refined, it heralds a paradigm shift in cancer treatment evaluation, with rippling benefits for patients, clinicians, and research worldwide.

Subject of Research: People

Article Title: Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study

News Publication Date: 17-Jun-2026

Web References:

• The Lancet Oncology: http://dx.doi.org/10.1016/S1470-2045(26)00084-7
• Mesothelioma AI model (ARTIMES): https://huggingface.co/nki-radiology/ARTIMES
• EU Medical Devices Regulation: https://health.ec.europa.eu/medical-devices-sector/new-regulations_en

References:
Groot Lipman K, Burgers S, et al. Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study. The Lancet Oncology, 2026.

Image Credits: ©Netherlands Cancer Institute

Keywords: Cancer treatments, Artificial intelligence, Imaging analysis, Pleural mesothelioma, Tumor volumetrics, Clinical trials, Precision oncology

University of Michigan Rogel Cancer Center researchers have unveiled a groundbreaking metabolic mechanism that colorectal cancer cells exploit to maintain exceptionally high iron levels, a discovery that opens promising avenues for targeted cancer therapies. Published recently in Cell Metabolism, this study provides an unprecedented insight into how tumor cells sidestep iron toxicity and evade a form of cell death known as ferroptosis, potentially revolutionizing the understanding of metal metabolism in cancer biology.

Colorectal cancer cells are known to harbor elevated iron concentrations, far surpassing those found in healthy cells. Iron is a double-edged sword in cellular physiology—essential for processes like DNA synthesis and cell proliferation but lethal in excess due to its propensity to generate harmful reactive oxygen species. Ordinarily, cells with excessive iron succumb to ferroptosis, a specialized form of oxidative cell death driven by iron-mediated lipid peroxidation. Tumor cells subvert this natural safeguard, sustaining iron overload without triggering their own demise, but how they achieve this has remained elusive—until now.

The investigative team led by Dr. Yatrik Shah, Horace W. Davenport Collegiate Professor of Physiology at Michigan Medicine, employed a metabolism-directed CRISPR screening approach to systematically dissect the pathways protecting colorectal cancer cells from iron-induced oxidative damage. Surprisingly, canonical ferroptotic enzymes, previously presumed central to this resistance, were found non-essential for tumor survival. This redirected focus led the scientists to explore mitochondrial metabolism more profoundly.

Their research unveiled that the mitochondrial enzyme complex II plays a pivotal role in safeguarding cancer cells from iron-induced toxicity. Complex II regulates coenzyme Q (CoQ) within mitochondria, a key antioxidant molecule that quells oxidative stress. By fine-tuning CoQ’s redox state, complex II effectively buffers the destructive potential of accumulated iron, preventing ferroptosis and enabling cancer cell proliferation. When researchers knocked out complex II in colorectal cancer models, iron toxicity became unmanageable for the tumor cells, leading to widespread cell death and marked tumor growth inhibition.

Crucially, complex II’s protective mechanism appears specific to the high-iron environment of cancer cells. In mouse models, disruption of complex II elicited negligible adverse effects on normal tissues, underscoring the therapeutic potential of selectively targeting this mitochondrial axis in colorectal cancer. This specificity addresses a significant hurdle in oncology: minimizing treatment toxicity while maximizing antitumor efficacy.

Further intricacies emerged as the study revealed a feedback loop wherein iron itself modulates complex II activity, suggesting a sophisticated regulatory axis that maintains iron homeostasis within tumors. This bidirectional interaction offers additional molecular targets for disrupting iron tolerance in cancer cells and deepening our understanding of tumor metabolism.

These findings represent a paradigm shift from earlier hypotheses centered on canonical ferroptosis regulators, highlighting the necessity of focusing on mitochondrial metabolism in cancer research. By leveraging sophisticated genome-editing tools and bioenergetic profiling, the Rogel Cancer Center team charted a novel course for drug discovery efforts aimed at crippling iron addiction—a hallmark of not only colorectal but potentially many other malignancies.

The next phase of this research endeavors to identify and develop potent inhibitors of complex II or its associated metabolic pathways. Given that dysregulated iron metabolism is a common vulnerability across diverse cancer types, these interventions could herald a new era of broad-spectrum anticancer strategies. Moreover, detailed characterization of iron complex II interplay might uncover additional metabolic dependencies exploitable for therapeutic gains.

This transformative research underscores the intricate metabolic adaptations that empower colorectal cancers to circumvent intrinsic iron toxicity constraints. By illuminating the heme-complex II axis as a linchpin in maintaining oxidative balance amid iron overload, it offers a highly selective target for the design of next-generation anticancer agents.

Researchers anticipate that combining complex II inhibition with other therapies may amplify treatment responses and overcome resistance mechanisms. As the quest to outsmart cancer evolves, this study reinforces the vital role of mitochondrial metabolism understanding in crafting innovative clinical interventions.

In sum, the University of Michigan team’s discovery of complex II’s role in buffering iron toxicity not only deciphers a long-standing biological enigma but also charts a compelling translational pathway. It epitomizes how fundamental metabolic insights can accelerate the development of precision treatments conferring hope to millions affected by colorectal cancer worldwide.

Subject of Research: Cells
Article Title: Iron addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death
News Publication Date: June 17, 2026
Web References: http://dx.doi.org/10.1016/j.cmet.2026.04.020
References: “Iron addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death,” Cell Metabolism, DOI: 10.1016/j.cmet.2026.04.020
Image Credits: Shah Lab, Rogel Cancer Center
Keywords: Colorectal cancer, iron metabolism, ferroptosis, complex II, coenzyme Q, mitochondrial metabolism, oxidative cell death, tumor metabolism, cancer therapy

In a groundbreaking study led by The University of Texas MD Anderson Cancer Center, researchers have unveiled compelling insights into how radiation therapy can profoundly influence the immune landscape of brain metastases, opening new avenues for combinational immunotherapeutic strategies. Brain metastases, secondary tumors that originate from cancers elsewhere in the body and colonize the brain, represent one of the most formidable clinical challenges in oncology. Their treatment has been notoriously difficult due to the highly immunosuppressive nature of the brain tumor microenvironment and the protective blood-brain barrier, which together blunt the effectiveness of conventional immunotherapies.

Despite the advances in immune checkpoint inhibitors and cellular therapies that have revolutionized treatment for many cancers, these modalities have shown limited success in brain metastases. The prevailing concept attributes this resistance largely to the “cold” immune microenvironment within the brain, characterized by suppressed immune activation and poor T cell infiltration. Radiation therapy, traditionally employed for its cytotoxic effects on cancerous cells, has garnered interest as a potential immunomodulatory agent. However, the precise mechanisms by which radiation alters immune dynamics within brain metastases remained elusive until now.

Leveraging an integrative approach encompassing RNA sequencing and T cell receptor (TCR) profiling on samples from over 300 patients harboring brain metastases sourced predominantly from breast and lung primaries, the research team decoded the complex interplay between radiation and immune activation. Their findings, recently published in Clinical Cancer Research, reveal that pre-operative radiation not only directly damages tumor DNA but also reshapes the tumor microenvironment through enhanced recruitment and activation of cytotoxic T lymphocytes. This dual impact fundamentally transforms the previously immunologically inert metastatic lesions into immunologically responsive entities.

Mechanistically, radiation induces the release of tumor-associated antigens and danger signals, which act as potent stimulators for antigen-presenting cells and infiltrating lymphocytes. This cascade prompts an upregulation of inflammatory cytokines and immune checkpoints, effectively increasing tumor visibility to the immune system. Interestingly, radiation also modulates tumor vasculature, facilitating enhanced permeability and immune cell trafficking into the tumor bed. Concurrently, suppressive myeloid populations within the microenvironment are either depleted or reprogrammed, further alleviating immunosuppression.

One of the study’s pivotal revelations centers on T cell receptor diversity as a prognostic biomarker. Enhanced TCR diversity corresponds with better immunotherapeutic outcomes, suggesting that radiation-induced augmentation of this diversity might predict patient responsiveness. Such biomarkers hold immense clinical promise, enabling personalized treatment algorithms that optimize radiation-immunotherapy combinations tailored to individual tumor immune profiles.

Dr. Jason Huse, M.D., Ph.D., a leading pathologist at MD Anderson and co-senior author, emphasizes the transformative nature of these findings. “Our results demonstrate that instead of merely bypassing the blood-brain barrier, we should recalibrate our therapeutic focus toward the tumor microenvironment itself. Radiation effectively ‘primes’ these metastases, enabling robust immune engagement that was previously unattainable. This paradigm shift paves the way for clinical trials harnessing synergistic radiation and immunotherapy regimens.”

This shift is particularly significant given the limitations of systemic therapies in penetrating brain lesions. By directly modifying the local immune milieu, radiation circumvents longstanding pharmacologic barriers and leverages the body’s own immune arsenal for tumor eradication. The implications extend beyond localized control; emerging evidence hints at the potential for abscopal effects where immunity induced in the irradiated site mediates systemic antitumor responses.

The research incorporated tissue specimens from a contemporaneous clinical trial spearheaded by Dr. Debra Nana Yeboa, which contrasted pre-operative and postoperative radiation regimens. This comparative analysis reinforced the immunomodulatory superiority of pre-operative radiation, highlighting its capacity to bolster immune infiltration and activation before surgical tumor resection.

While the experimental findings are preliminary and retrospective, the investigators are actively validating these observations in larger, prospective clinical cohorts. The overarching goal is to delineate optimized therapeutic windows and dosing sequences that exploit radiation’s immunogenic potential in concert with checkpoint inhibitors, vaccines, or adoptive cell therapies.

In summary, this study delineates a critical and previously underappreciated function of radiation therapy in rendering brain metastases immunologically “hot.” By integrating radiation with immunotherapeutic modalities, there is a tangible prospect of overcoming the entrenched resistances posed by the brain’s unique protective and suppressive environment. This work marks a pivotal step toward improved survival rates and quality of life for patients afflicted with metastatic brain tumors.

As the oncology community eagerly anticipates forthcoming clinical trials, this research provides an urgent biological rationale for a comprehensive therapeutic strategy that targets both tumor cells and their microenvironment. The convergence of radiation biology and immunotherapy represents a new frontier with the capacity to redefine standard-of-care paradigms for brain metastases.

Subject of Research: The immunomodulatory effects of radiation therapy on brain metastases and the tumor immune microenvironment.

Article Title: Ionizing Radiation Enhances Prognostically Relevant Immune Signatures in Brain Metastases, Paving the Way for Combined Radiation-Immunotherapy Approaches.

News Publication Date: June 17, 2026

Web References:

• MD Anderson Cancer Center
• Clinical Cancer Research Journal

Image Credits: The University of Texas MD Anderson Cancer Center

Keywords: Brain metastases, Tumor microenvironment, Radiation therapy, Immunotherapy, T cell receptor diversity, Immune modulation, Blood-brain barrier, Cytotoxic T cells, Immune checkpoints, Biomarkers, Clinical oncology, Cancer treatment